Results 51 to 60 of about 6,549 (182)

Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters

Frontiers in Oncology, 2021
PurposeExplaining why 90Y TOF-PET based equivalent uniform dose (EUD) using recommended manufacturer FDG reconstruction parameters has been shown to predict response.MethodsThe hot rods insert of a Jaszczak deluxe phantom was partially filled with a 2.65
Michel Hesse, Philipe d’Abadie, Renaud Lhommel, Francois Jamar, Stephan Walrand   +4 more
doaj   +1 more source

MVP-Assisted Temporary Vascular Occlusion during ⁹⁰Y Radioembolization: A Case Report

Journal of Clinical Interventional Radiology ISVIR
Yttrium-90 radioembolization is an effective treatment for liver cancers. However, deposition of radioactive microspheres in nondiseased liver can result in parenchymal injury.
John J. Park, Franz Edward Boas, Federico Pedersoli   +2 more
doaj   +1 more source

Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla

Case Reports in Hepatology, 2014
We report a case of safe and successful yttrium-90 resin microsphere radioembolization in a patient with a long history of multiple recurrent colon cancer hepatic metastases progressing after hepatic resections, hepatic arterial chemotherapy, and ...
Vlasios S. Sotirchos, Elena N. Petre, Karen T. Brown, Lynn A. Brody, Michael I. D’Angelica, Ronald P. DeMatteo, Nancy E. Kemeny, Constantinos T. Sofocleous   +7 more
doaj   +1 more source

Chemoembolization and Radioembolization for Hepatocellular Carcinoma [PDF]

Clinical Gastroenterology and Hepatology, 2013
Hepatocellular carcinoma (HCC) continues to represent a major worldwide problem. Although treatments such as resection, transplantation, and ablation may provide a chance for a cure, these options are often precluded because of advanced disease presentation. Palliative treatments include transarterial embolization and systemic therapies.
Riad, Salem, Robert J, Lewandowski
openaire   +2 more sources

Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization

Current Oncology, 2021
Background: Trans-arterial radioembolization (TARE) has shown promising results in treating hepatocellular carcinoma (HCC). We identified independent predictors of radiological complete response (CR) in patients with intrahepatic HCC who were treated ...
Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim   +7 more
doaj   +1 more source

Acute Upper Gastrointestinal Bleeding is Associated With Poor Prognosis in Patients With Biliary Tract Cancer

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Aim Upper gastrointestinal bleeding (UGIB) is associated with an unfavorable outcome in cancer patients. In patients with biliary tract cancer (BTC), data on the incidence, management, and prognostic implications of UGIB are limited. This study investigated the prevalence, treatment efficacy, and prognostic factors associated with UGIB in BTC.
Jan Christoph Schumacher, Sonja Lang, Philipp Kasper, Anna Martin, Dirk Waldschmidt, Martin Bürger, Ulrich Töx, Christoph Neumann‐Haefelin, Gabriel Allo   +8 more
wiley   +1 more source

Diagnosis and management of radiation cholecystitis as a complication of Y90 radioembolization for hepatocellular carcinoma

Radiology Case Reports
Radiation induced cholecystitis is a known but rare complication of Yttrium90 (Y90) radioembolization of hepatic tumors due to nontarget embolization. Many documented cases of radiation induced cholecystitis have been treated with cholecystectomy, which ...
Joe Khoury, DO, MBA, Brenden Li, BS, Joyce Zhu, BS, Trevor Lin, BS, Eusha Hasan, BA, Ashley Lamba, BS, Vaiva Gustainyte, DO, Hakob Kocharyan, MD, Christopher Yeisley, MD, Elias Salloum, MD, Altan Ahmed, MD, Craig Greben, MD, Mustafa Al-Roubaie, MD   +12 more
doaj   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, Volume 41, Issue 6, Page 1701-1721, June 2026.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Efficacy and Safety of Transarterial Radioembolization in Elderly Patients with Hepatocellular Carcinoma: A Single-Center Experience

The Turkish Journal of Gastroenterology
Background/Aims: Hepatocellular carcinoma is a major cause of mortality and morbidity in both cirrhotic and non-cirrhotic patients, and most patients are suitable for locoregional and/or systemic therapy at the time of diagnosis.
Ümit Karaoğullarından, Yüksel Gümürdülü, Oğuz Üsküdar, Emre Odabaş, Hasan Selim Güler, Cansu Geçkalan, Burcu Aslan Benli, Anıl Delik , Asena Ayça Özdemir, Sedef Kuran   +9 more
doaj   +1 more source

Transarterial therapy: An evolving treatment modality of hepatocellular carcinoma

The Saudi Journal of Gastroenterology, 2014
Liver cancer is the fifth most common cancer in men, the seventh most common in women, and the third most common cause of death from cancer worldwide.
Khalid A Jazieh, Mohammad Arabi, Azzam A Khankan   +2 more
doaj   +1 more source